Alprazolam 0.25mg tablets recalled for potential cross contamination
Preferred Pharmaceuticals is recalling Alprazolam 0.25mg tablets (Lot G1822K, expiration 5/31/2023) nationwide due to potential cross contamination from manufacturing deviations. No illnesses have been reported.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA Class II recall with manufacturing deviations creating potential cross-contamination risk, classified as a risk-of-harm product where injury has not yet been reported. No illnesses or injuries have been reported.
Plain-English summary
Preferred Pharmaceuticals, Inc. is recalling Alprazolam tablets, USP 0.25mg in 30-count bottles (NDC 68788-7594-3, Lot G1822K, expiration date 5/31/2023). The product is a prescription benzodiazepine medication.
The recall is a downstream action resulting from manufacturing deviations at Breckenridge Pharmaceuticals, Inc., which manufactures the product. These deviations created a potential risk of cross contamination during production.
The affected product was distributed nationwide in the United States. No illnesses or injuries have been reported to date. Consumers who have this medication should consult their healthcare provider about whether to continue use and proper disposal options. Healthcare providers should inform patients who may have received this lot.
The recalled product
- Product
- Alprazolam Tab, USP 0.25mg, (CIV), 30-count bottle, Rx Only, Preferred Pharmaceuticals, Inc. Manufactured by: Breckenridge Pharmaceuticals, Inc., Boca Raton, FL. Ins:NDC 68788-7594-3
- Manufacturer
- Preferred Pharmaceuticals, Inc.
- Category
- Drug — Benzodiazepine
- Hazard
- cross-contamination
- cgmp-deviation
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot: G1822K
- Exp. Date:5/31/2023.
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27